MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.7111 -0.0137 (-1.89%)
Streaming Delayed Price Updated: 9:58 AM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Lexaria Bioscience (NASDAQ: LEXX) Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD
Via Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM)
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
Via CannabisNewsWire
News headline image
Why Lexaria Shares Are Rising Today ↗
Lexaria Bioscience Corp (NASDAQ:LEXX) is trading higher We... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
Via Investor Brand Network
News headline image
Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study ↗
Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
Via Investor Brand Network
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension
Via Investor Brand Network
News headline image
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
Kelowna, British Columbia – TheNewswire - December 16, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms... 
Via TheNewswire.com
News headline image
Lexaria Bioscience Committed to Innovation and Improving Quality of Life ↗
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Committed to Innovation and Improving Quality of Life
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via CannabisNewsWire
News headline image
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B ↗
Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Exceeding $160B
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Reshape Lifesciences (NASDAQ:RSLS... 
Via Benzinga
News headline image
52 Biggest Movers From Yesterday ↗
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via Investor Brand Network
News headline image
Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference ↗
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of... 
Via Benzinga
News headline image
35 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
Via Investor Brand Network
News headline image
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket? ↗
Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story